Pyrosequencing AB raises sek 1.000 million in initial public offering at sek 100 per share

PYROSEQUENCING AB RAISES SEK 1.000 MILLION IN INITIAL PUBLIC OFFERING AT SEK 100 PER SHARE Pyrosequencing AB ("Pyrosequencing") today priced the Initial Public Offering ("Offering") of its shares on the OM Stockholm Exchange. 10 million shares are being sold in the Offering at SEK 100 resulting in a total offering size of SEK 1.000 million (approximately US$ 115 million). The issue was substantially oversubscribed. In addition, Pyrosequencing has granted an over-allotment option to the underwriters of the Offering to issue an additional 1.5 million shares within 30 days of the start of the trading of the shares on the OM Stockholm Stock Exchange. Subsequent to the completion of the Offering, Pyrosequencing's free float will be approximately 28.8% (approximately 31.7% if the over-allotment option is exercised). Shares were offered to institutional investors worldwide and to retail investors in Sweden. A limited number of shares were also reserved for employees of Pyrosequencing. Erik Wallden, President and CEO of the company, noted: 'We are very happy with the good reception of Pyrosequencing by global investors and are particularly pleased with the geographic broadening of our shareholder base". Pyrosequencing shares are to be listed on the OM Stockholm Exchange under the symbol "PYRO". It is expected that the shares will commence trading on Friday, 30 th June. Deutsche Bank acted as global co-ordinator and bookrunner of the Offering, with Alfred Berg and SG Cowen as co-lead managers. Pyrosequencing develops, manufactures and markets complete systems for applied genetic analysis based on its proprietary Pyrosequencing TM technology. Applied genetic analysis may be used for drug development, drug selection and diagnostics. Pyrosequencing's technology addresses the increasing demand for applied genetic analysis across various markets, including research and clinical routine testing and large-scale customised industrial applications such as drug development by pharmaceutical companies. The information contained herein is not for publication or distribution to persons in the United States of America, Canada, the United Kingdom, Australia or Japan. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold without registration thereunder or pursuant to an available exemption therefrom. These materials do not constitute an offer of securities for sale in the United States. For further information: Pyrosequencing AB Erik Walldén (+46 18 56 59 00) (+46 70 326 98 70) Deutsche Bank Ian Crosbie (+44 20 7547 4873) Marcus LeGrice (+44 20 7545 6736) ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/2000/06/22/20000622BIT00460/bit0001.doc http://www.bit.se/bitonline/2000/06/22/20000622BIT00460/bit0002.pdf